Shanghai-based biopharmaceutical company Harbour BioMed today announced that it had raised US$85 million series B round led by Government of Singapore Investment Corp (GIC).New investors including China Life Investment and Vertex Ventures, as well as existing investors Advantech Capital and Legend Capital also participated in this round. Harbour BioMed was established in December 2016 around a series A round of $50 million and the acquisition of the Netherlands-based fully human transgenic antibody technology company, Harbour Antibodies BV and its subsidiaries. …

GIC Leads $85M Series B Round In Chinese Biotech Firm Harbour BioMed appeared first on China Money Network.